Company intelligence / Profile preview

Thorasys

Montreal, Quebec, Canadathorasys.com ↗

Ownership: Private
Employees: ~36
Development stage: Commercial

Overview

The company’s tremoflo C‑100 AOS provides effortless quantitative assessment of airway function using oscillometry. It has been validated in clinical settings for detecting changes in impedance related to COPD and other lung diseases. The system enables point-of-care diagnostics with minimal patient effort.

Therapeutic areas: Pulmonology
Modalities: DeviceSoftware (for pulmonary function assessment)
Industry: Physiological Monitoring

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed; interest from research institutions and medical device distributors noted.

Beyond the preview

Go deeper on Thorasys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thorasys.

Explore the full profile